Compare Stocks → Crypto Market Preps For Trillions Worth of Inflows! (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKCAOTCMKTS:BLUSFOTCMKTS:CYDYNASDAQ:TBPHNASDAQ:YMAB Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKCAAkcea Therapeutics$18.17$18.16$8.00▼$21.70$1.85B1.45361,806 shsN/ABLUSFBELLUS Health$9.77$0.49▼$2.60$2.35B1.5539,610 shs3.45 million shsCYDYCytoDyn$0.16$0.17$0.15▼$0.42$164.84M0.213.15 million shs2.70 million shsTBPHTheravance Biopharma$8.97-0.4%$9.01$8.21▼$12.03$433.96M0.36358,452 shs401,710 shsYMABY-mAbs Therapeutics$16.26-1.5%$14.85$3.13▼$20.90$722.32M0.75364,047 shs270,332 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKCAAkcea Therapeutics0.00%0.00%0.00%0.00%0.00%BLUSFBELLUS Health0.00%0.00%0.00%0.00%+106.44%CYDYCytoDyn-2.01%+0.59%+2.03%-16.28%-57.04%TBPHTheravance Biopharma-0.44%+0.11%-7.43%-20.20%-16.32%YMABY-mAbs Therapeutics-1.45%-4.01%-1.45%+138.42%+401.85%Grab Your Free Bitcoin Today! (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKCAAkcea TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABLUSFBELLUS HealthN/AN/AN/AN/AN/AN/AN/AN/ACYDYCytoDynN/AN/AN/AN/AN/AN/AN/AN/ATBPHTheravance Biopharma1.9073 of 5 stars3.51.00.00.02.42.50.6YMABY-mAbs Therapeutics0.7694 of 5 stars1.12.00.00.02.84.20.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKCAAkcea TherapeuticsN/AN/AN/AN/ABLUSFBELLUS HealthN/AN/AN/AN/ACYDYCytoDynN/AN/AN/AN/ATBPHTheravance Biopharma3.00Buy$20.00122.97% UpsideYMABY-mAbs Therapeutics2.29Hold$16.571.92% UpsideCurrent Analyst RatingsLatest YMAB, TBPH, AKCA, CYDY, and BLUSF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/6/2024YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $22.003/4/2024YMABY-mAbs TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $26.003/4/2024YMABY-mAbs TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$16.00 ➝ $26.002/20/2024YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $21.002/12/2024YMABY-mAbs TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.00 ➝ $18.001/8/2024TBPHTheravance BiopharmaEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Inline(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKCAAkcea Therapeutics$488.54M3.78$0.51 per share35.54$5.78 per share3.14BLUSFBELLUS Health$30K0.00N/AN/A$0.25 per share0.00CYDYCytoDyn$270K598.24N/AN/A($0.12) per share-1.36TBPHTheravance Biopharma$57.42M7.52N/AN/A$4.28 per share2.10YMABY-mAbs Therapeutics$84.82M8.39N/AN/A$2.32 per share7.01Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKCAAkcea Therapeutics$40.77M$0.48N/AN/AN/A-12.34%-8.94%-8.02%N/ABLUSFBELLUS Health-$7.01M-$0.10N/AN/AN/A-49,910.34%-48.37%-45.25%N/ACYDYCytoDyn-$79.82M-$0.06N/A∞N/AN/AN/A-449.49%4/6/2024 (Estimated)TBPHTheravance Biopharma-$55.19M-$0.97N/AN/AN/A-96.12%-19.31%-12.03%5/13/2024 (Estimated)YMABY-mAbs Therapeutics-$21.43M-$0.49N/AN/AN/A-25.26%-20.72%-16.28%5/13/2024 (Estimated)Latest YMAB, TBPH, AKCA, CYDY, and BLUSF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/29/2024Q4 2023YMABY-mAbs Therapeutics-$0.19-$0.02+$0.17-$0.02$21.72 million$23.36 million2/26/2024Q4 2023TBPHTheravance Biopharma-$0.15-$0.17-$0.02-$0.17$17.49 million$17.57 million1/16/2024Q2 2024CYDYCytoDynN/A-$0.01-$0.01-$0.01N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKCAAkcea TherapeuticsN/AN/AN/AN/AN/ABLUSFBELLUS HealthN/AN/AN/AN/AN/ACYDYCytoDynN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/AYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKCAAkcea TherapeuticsN/A12.1711.78BLUSFBELLUS HealthN/A13.8713.87CYDYCytoDynN/A0.070.07TBPHTheravance BiopharmaN/A5.395.39YMABY-mAbs TherapeuticsN/A5.525.27OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKCAAkcea Therapeutics19.27%BLUSFBELLUS HealthN/ACYDYCytoDyn5.06%TBPHTheravance Biopharma99.10%YMABY-mAbs Therapeutics70.85%Insider OwnershipCompanyInsider OwnershipAKCAAkcea Therapeutics1.50%BLUSFBELLUS Health24.17%CYDYCytoDyn0.71%TBPHTheravance Biopharma5.30%YMABY-mAbs Therapeutics21.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKCAAkcea Therapeutics248101.60 millionN/AOptionableBLUSFBELLUS Health10159.12 millionN/ANot OptionableCYDYCytoDyn12989.43 million982.41 millionNot OptionableTBPHTheravance Biopharma35948.17 million45.61 millionOptionableYMABY-mAbs Therapeutics10043.78 million34.37 millionOptionableYMAB, TBPH, AKCA, CYDY, and BLUSF HeadlinesSourceHeadlineWall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Betzacks.com - March 28 at 10:56 AMY-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 3.9%marketbeat.com - March 26 at 12:38 PMYmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?zacks.com - March 20 at 8:40 AMY-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 4.3%marketbeat.com - March 19 at 11:57 AMY-mAbs Therapeutics Finance Chief Bo Kruse Resignsmarketwatch.com - March 15 at 8:31 AMY-mAbs Therapeutics, Inc.: Y-mAbs Therapeutics Announces Resignation of Chief Financial Officerfinanznachrichten.de - March 14 at 2:58 PMY-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $15.84marketbeat.com - March 14 at 11:56 AMY-mAbs Therapeutics CFO Bo Kruse To Retiremarkets.businessinsider.com - March 14 at 9:57 AMY-mAbs Therapeutics Announces Resignation of Chief Financial Officerglobenewswire.com - March 14 at 9:05 AMGSA Capital Partners LLP Acquires 92,765 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)marketbeat.com - March 13 at 5:32 AMWall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?zacks.com - March 12 at 10:55 AMBAMF, Corewell Health partner on clinical trial for advanced cancer treatmentcrainsgrandrapids.com - March 11 at 3:17 PMY-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Down 8.3%marketbeat.com - March 11 at 11:52 AMY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Holdings Raised by Trexquant Investment LPmarketbeat.com - March 11 at 5:14 AMCracking The Code: Understanding Analyst Reviews For Y-mAbs Therapeuticsmarkets.businessinsider.com - March 6 at 6:21 PMY-mAbs Therapeutics (NASDAQ:YMAB) Shares Up 8.2% Following Analyst Upgrademarketbeat.com - March 6 at 11:45 AMHC Wainwright Raises Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $22.00marketbeat.com - March 6 at 8:25 AMAre You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choicezacks.com - March 5 at 1:01 PMY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 4 at 1:15 PMY-mAbs Therapeutics (NASDAQ:YMAB) Price Target Raised to $26.00 at Canaccord Genuity Groupmarketbeat.com - March 4 at 10:25 AMY-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directorsglobenewswire.com - March 4 at 7:30 AMY-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directorsglobenewswire.com - March 4 at 7:30 AMY-mAbs Therapeutics Full Year 2023 Earnings: Beats Expectationsfinance.yahoo.com - March 3 at 2:52 PMQ4 2023 Y-mAbs Therapeutics Inc Earnings Callfinance.yahoo.com - March 2 at 1:35 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAkcea TherapeuticsNASDAQ:AKCAAkcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.BELLUS HealthOTCMKTS:BLUSFBELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.CytoDynOTCMKTS:CYDYCytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.Theravance BiopharmaNASDAQ:TBPHTheravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.Y-mAbs TherapeuticsNASDAQ:YMABY-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.